http://www.businesswire.com/news/home/20260613776510/en/NNOX-Investors-Have-Opportunity-to-Lead-Nano-X-Imaging-Ltd.-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm 2026-06-13T19:24:00.000-07:00 weekly 0.5 http://www.businesswire.com/news/home/20260613313708/en/MSFT-Investors-Have-Opportunity-to-Lead-Microsoft-Corporation-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm 2026-06-13T19:13:00.000-07:00 weekly 0.5 http://www.businesswire.com/news/home/20260613018476/en/Gay-Qatari-Refugee-Returns-to-Face-Qatar-at-the-World-Cup-Standing-With-Senator-Scott-Wiener-to-Say-Love-Is-Not-a-Crime 2026-06-13T10:42:00.000-07:00 weekly 0.5 http://www.businesswire.com/news/home/20260610278575/en/Genmab-Announces-Epcoritamab-Monotherapy-and-Epcoritamab-Based-Combination-Regimens-Demonstrate-High-Response-Rates-in-Elderly-Patients-with-Newly-Diagnosed-Diffuse-Large-B-Cell-Lymphoma-DLBCL 2026-06-13T09:45:00.000-07:00 weekly 0.5 http://www.businesswire.com/news/home/20260613021335/en/Incyte-Announces-New-Positive-Data-at-EHA-2026-Showed-INCA033989-Achieved-Rapid-Robust-and-Sustained-Clinical-and-Molecular-Responses-and-Was-Well-Tolerated-in-Patients-with-Myelofibrosis-and-Essential-Thrombocythemia 2026-06-13T08:15:00.000-07:00 weekly 0.5 http://www.businesswire.com/news/home/20260613138727/en/Dr.-Reddy%E2%80%99s-Announces-the-First-to-Market-Launch-of-Bosutinib-Tablets-400mg-a-Generic-Equivalent-of-Bosulif%C2%AE-in-the-United-States 2026-06-13T03:22:00.000-07:00 weekly 0.5 http://www.businesswire.com/news/home/20260613831839/en/Results-from-Incyte%E2%80%99s-Pivotal-Phase-3-frontMIND-Trial-of-Tafasitamab-Monjuvi%C2%AEMinjuvi%C2%AE-Combination-Presented-at-the-2026-European-Hematology-Association-EHA-Congress-Plenary-Showed-Prolonged-Progression-Free-Survival 2026-06-13T03:00:00.000-07:00 weekly 0.5